三阴性乳腺癌患者化疗后血糖血脂代谢状况及其影响因素的分析

The Metabolism of Blood Glucose and Lipid and Its Influence Factors Analysis in Triple-Negative Breast Cancer Patients after Chemotherapy

摘要: 目的：探究三阴性乳腺癌(TNBC)患者首次接受标准方案化疗前和化疗后血糖血脂代谢状况的差异，并分析其影响因素。方法：回顾性收集2013年1月~2020年1月年期间就诊于青岛大学附属医院并首次接受化疗治疗的TNBC患者。通过检测患者化疗前、后血糖血脂水平，分析血糖血脂代谢状况的变化及其影响因素。结果：251例TNBC患者，化疗前、化疗后中位血糖水平分别为：5.13 mmol/L、5.59 mmol/L；化疗前、化疗后中位总胆固醇(TC)水平分别为：5.17 mmol/L、5.64 mmol/L；化疗前、化疗后中位低密度脂蛋白(LDL)水平分别为：3.00 mmol/L、3.34 mmol/L；差异均有统计学意义(P < 0.05)。是否绝经与化疗后血糖、TC和LDL代谢相关。不同化疗方式、化疗方案以及化疗周期长短与化疗后患者的血糖血脂水平相关(P < 0.05)。结论：TNBC患者首次接受标准方案化疗后可出现血糖、血脂代谢紊乱，需要关注TNBC患者化疗后增加的罹患心血管疾病潜在的风险。

Abstract: Objective: To analyze the difference of blood glucose and lipid metabolism in triple-negative breast cancer (TNBC) patients after chemotherapy with standard regimens for the first time, and to analyze its influencing factors to provide evidence for monitoring cardiovascular risk factors in TNBC patients after chemotherapy. Methods: From January 2013 to January 2020, TNBC patients who were admitted to the Affiliated Hospital of Qingdao University and received chemotherapy for the first time were collected. By monitoring the blood glucose and lipid levels before and after chemotherapy, the changes of blood glucose and lipid metabolism and its influencing factors are analyzed. Results: 251 TNBC patients were enrolled. The median blood glucose levels before chemotherapy were 5.13 mmol/L, lower than 5.59 mmol/L after chemotherapy (P < 0.05). The median total cholesterol (TC) levels before chemotherapy were 5.17 mmol/L, lower than 5.64 mmol/L after chemotherapy (P < 0.05). The median low-density lipoprotein (LDL) levels before chemotherapy were 3.00 mmol/L, lower than 3.34 mmol/L after chemotherapy (P < 0.05). The menopausal status of patients is related to blood glucose, TC and LDL metabolism. Different chemotherapy methods, chemotherapy regimens and the length of the chemotherapy cycle are related to the blood glucose and blood lipid levels (P < 0.05). Conclusion: TNBC patients may have blood glucose and lipid metabolism disorders after receiving standard chemotherapy for the first time. It is necessary to pay attention to the increased potential risk of cardiovascular disease in TNBC patients after chemotherapy.